- Switzerland's Sandoz has set the share price for its industrial chemical division Clariant's flotation at between 360 and 410 Swiss francs ($310.4 and $353.5). Gross proceeds before commissions and expenses should be between 2.19 billion and 2.39 billion francs, says the company. Meantime, Clariant expects to build new plants and service centers in Asia to meet an expected rise in sales. Clariant currently accounts for 22% of group sales, and this is expected to rise to about one third over the next few years, according to the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze